Improving Clinical Trial Diversity Is Critical to Health Equity
Clinical trial diversity helps to ensure we have medications that are suited to reflect and treat the intended treatment population. That’s why our entire industry came together to develop and voluntarily adopt principles on closing the diversity gaps.
Understanding the challenges of the past are helping us improve the future. See how we’re taking action.
PhRMA Launches First-ever Industry-Wide Principles on Clinical Trial Diversity
Moving Forward on Clinical Trials Diversity: A Conversation
Hear PhRMA President and CEO Stephen J. Ubl and Novartis CEO Vas Narasimhan discuss the importance of diversity in clinical trials, including industry principles that drive this work and how these efforts can help build trust in underserved communities.
As we endeavor to push forward to change the future, we must first understand the past. Colonization, slavery, segregation, systemic racism—these experiences continue to disproportionately impact underserved communities and have created a foundation of mistrust rooted in history.
*This publication offers a limited number of free article views per month and then requires a subscription
Here is a small sampling of formative events in U.S. history that have shaped the relationship communities of color have with medical research and the health care system. This list is by no means exhaustive, but we hope it helps pave the way for candid dialogue that guides our work on equity.
Slavery
Gynecological Experimentation on Enslaved Women
Closing of Medical Schools and Exclusion of Future Health Providers
Birth Control Experimentation in Puerto Rico
The Tuskegee Syphilis Study
Henrietta Lacks
Radioactive Iodine
Slavery (1619 - 1865)
Gynecological Experimentation On Enslaved Women (1845 - 1849)
Closing Of Medical Schools and Exclusion Of Future Health Providers (1870)
Birth Control Experimentation in Puerto Rico (1930s - 1970s)
The Tuskegee Syphilis Study (1932 - 1972)
Henrietta Lacks (1951)
Radioactive iodine (1956 - 1957)
What We Do Matters; How We Do It Is Equally Important
A conversation on why a community-centric approach is needed to build trust, increase awareness, enhance clinical trial diversity and advance health equity.
